BioSpace News Archive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that management will present at the 2023 Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:00 a.m. ET.

Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.

ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases, will present the first set of clinical data from its lead asset, ZB131, directed against cancer-specific plectin (CSP), during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Summit Pharmaceuticals International has signed an exclusive distributorship agreement in Japan with EVERZOM, SAS*., a France-based company providing exosome manufacturing service.

BostonGene announced today the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics solutions that provide a holistic view of a patient’s disease by integrating multiple AI-based molecular and immune profiling techniques that analyze tumor, microenvironment, and host immunity.

CureALS, a pioneering nonprofit organization dedicated to eliminating ALS and other complex neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Frontotemporal Dementia, has officially launched.

International medical imaging IT and cybersecurity company Sectra reports that sales and operating profit for the fourth quarter and for the fiscal year exceeded previous records and recurring revenue increased.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that, with sponsorship and support from multiple physician specialty societies, the American Medical Association (“AMA”) has established three new Current Procedural Terminology (“CPT®’) Category 1 codes for MRI-Monitored Transurethral Ultrasound Ablation (“TULSA”) of prostate tissue, performed using Profound’s TULSA-PRO® system.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, announced a presentation reporting durable continuous transfusion independence with imetelstat, the Company’s first-in-class telomerase inhibitor, in IMerge Phase 3 lower risk MDS patients.

Lyra Therapeutics, Inc. announced that it has issued an equity-based award pursuant to its 2022 Inducement Award Plan to its Senior Vice President of Regulatory Affairs, Allison Nance, upon the commencement of her employment.